These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 17972514)

  • 21. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma.
    Lin CC; Yeh KH; Yang CH; Hsu C; Tsai YC; Hsu WL; Cheng AL; Hsu CH
    Anticancer Drugs; 2007 Jul; 18(6):703-8. PubMed ID: 17762400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Matsubara J; Shimada Y; Takashima A; Takahari D; Hirashima Y; Okita NT; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shirao K
    Jpn J Clin Oncol; 2008 Aug; 38(8):540-6. PubMed ID: 18628316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
    Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Taxol based chemotherapy in the treatment of advanced gastric cancer].
    Li Y; Wu XQ; Cui HJ; Tan HY
    Zhonghua Zhong Liu Za Zhi; 2004 Sep; 26(9):562-4. PubMed ID: 15555290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical study of comparison of CAF regimen and TP regimen in treatment of advanced breast cancer].
    Lin XG; Xie DR; Yao HR; Li ZH; Jiang ZM; Liu TH
    Ai Zheng; 2003 Apr; 22(4):411-4. PubMed ID: 12704001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
    Li M; Zhang J; Wang D; Zhong B; Tucker S; Lu C; Cheng J; Cao C; Xu J; Xu J; Pan H
    Anticancer Drugs; 2009 Nov; 20(10):941-5. PubMed ID: 19745719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer.
    Hara T; Omura K; Hirano M; Asada Y; Munemoto Y; Sakamoto J
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):631-6. PubMed ID: 16924496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis.
    Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase III randomized study comparing paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with advanced ovarian cancer.
    Mouratidou D; Gennatas C; Michalaki V; Papadimitriou A; Andreadis CH; Sykiotis C; Tsavaris N
    Anticancer Res; 2007; 27(1B):681-5. PubMed ID: 17348460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
    Im CK; Jeung HC; Rha SY; Yoo NC; Noh SH; Roh JK; Chung HC
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):315-21. PubMed ID: 18026677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility study of triplet combination chemotherapy of paclitaxel, cisplatin and S-1 for advanced gastric cancer.
    Fujitani K; Hasegawa H; Hirao M; Kurokawa Y; Tsujinaka T
    Anticancer Res; 2011 Sep; 31(9):3085-91. PubMed ID: 21868564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study of sequential methotrexate and 5-fluorouracil chemotherapy in previously treated gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group, JCOG 9207 trial.
    Hamaguchi T; Shirao K; Yamamichi N; Hyodo I; Koizumi W; Seki S; Imamura T; Honma H; Ohtsu A; Boku N; Mukai T; Yamamoto S; Fukuda H; Yoshida S;
    Jpn J Clin Oncol; 2008 Jun; 38(6):432-7. PubMed ID: 18515821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)].
    Yamamitsu S; Kimura H; Yamada Y; Inui N; Hiyama S; Hirata K; Kimura Y; Yamaguchi K; Shirasaka T
    Gan To Kagaku Ryoho; 2007 Sep; 34(9):1405-11. PubMed ID: 17876138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie.
    Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ;
    J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of paclitaxel and cisplatin for patients with advanced or recurrent gastric cancer.
    Nagata N; Kobayashi M; Kojima H; Kondo K; Hirabayashi N; Matsui T; Kataoka M; Takiyama W; Miyashita Y; Nakazato H; Araki K; Itoh H; Nakao A; Sakamoto J
    Hepatogastroenterology; 2005; 52(66):1905-10. PubMed ID: 16334804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study of combination chemotherapy with S-1 and low-dose cisplatin for highly advanced gastric cancer.
    Takahashi T; Saikawa Y; Yoshida M; Kitagawa Y; Otani Y; Kubota T; Kumai K; Kitajima M
    Anticancer Res; 2006; 26(2B):1631-5. PubMed ID: 16619584
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Lim JY; Cho JY; Oh KJ; Choi SH; Lee SI; Jeung HC
    Chemotherapy; 2009; 55(4):200-6. PubMed ID: 19451710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer.
    Nakajo A; Hokita S; Ishigami S; Miyazono F; Etoh T; Hamanoue M; Maenohara S; Iwashita T; Komatsu H; Satoh K; Aridome K; Morita S; Natsugoe S; Takiuchi H; Nakano S; Maehara Y; Sakamoto J; Aikou T;
    Cancer Chemother Pharmacol; 2008 Nov; 62(6):1103-9. PubMed ID: 18317763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-Fluorouracil, methotrexate, leucovorin, CDDP and epirubicin (FEPMTX): a wide-spectrum regimen of salvage chemotherapy for high-grade advanced gastric cancer.
    Kinoshita K; Yonemura Y; Sawa T; Miyata T; Sakuma H; Matsuki N; Tanaka S; Fushida S; Fujimura T; Mok YJ; Kim BS; Lee JI; Choi DW; Song YJ; Yang DH; Kwon SJ; Tanaka M; Miyazaki I
    Hepatogastroenterology; 2003; 50(53):1716-9. PubMed ID: 14571825
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.